Full Press Release Details
Alpha Tau Medical to Participate in Upcoming
September Investor Conferences
August 30, 2022 -- Alpha Tau Medical Ltd. (Nasdaq: DRTS) ("Alpha Tau"), the developer of the innovative alpha-radiation
cancer therapy Alpha DaRT , today announced the Company will participate in person at three
upcoming investor conferences in September 2022.
| Event: | Citi's 17th Annual BioPharma Conference |
| Date: | Wednesday, September 7,2022 |
| Location: | Boston, MA |
| Format: | 1:1 Meetings |
| Event: | Cantor Oncology, Hematology & HemeOnc Conference |
| Date: | Wednesday, September 28 th , 2022 |
| Location: | New York, NY |
| Format: | Group Panel and 1:1 Meetings |
| Event: | Ladenburg Thalmann Annual Healthcare Conference |
| Date: | Thursday, September 29 th , 2022 |
| Location: | New York, NY |
| Format: | Company Presentation and 1:1 Meetings |
Additional information can be found on the
Events and Presentations section of Alpha Tau's investor website, www.alphatau.com/events.
If you would like to schedule a 1:1 meeting, please contact the appropriate institutional representative.
Alpha DaRT (Diffusing Alpha-emitters
Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224
impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to
mainly affect the tumor, and to spare the healthy tissue around it.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that
focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology
was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Investor Relations Contact